证券代码：688670 证券简称：金迪克 公告编号：2025-035 江苏金迪克生物技术股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 江苏金迪克生物技术股份有限公司（以下简称"公司"）股票连续 2 个交 易日内（2025 年 11 月 10 日、2025 年 11 月 11 日）收盘价格涨幅偏离值累计达 到 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板股票异常交 易实时监控细则》的有关规定，属于股票交易异常波动。 经公司自查，并发函询证控股股东、实际控制人，截至本公告披露日， 公司不存在应披露而未披露的重大信息。公司目前生产经营正常，未发生重大 变化。 2025 年前三季度，公司营业收入 7,465.76 万元，同比增长 91.93%，归 属于上市公司股东的净利润-8,647.06 万元；归属于上市公司股东的扣除非经常 性损益的净利润-9,111.37 万元，处于亏损状态，预计 2025 年全年存在无法盈利 的 风 险 。 具 体 情 况 详 见 公 司 ...

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 上海市锦天城律师事务所 关于江苏金迪克生物技术股份有限公司 2025 年第一次临时股东大会的 1 上海市锦天城律师事务所 法律意见书 关于江苏金迪克生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 案号：01G20211960 致：江苏金迪克生物技术股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受江苏金迪克生物技术股 份有限公司（以下简称"公司"）委托，就公司召开 2025 年第一次临时股东大会 （以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股东会规则》等法律、法规和其他规范性文 件以及《江苏金迪克生物技术股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业 务管理办法》和《律师事务所证券法律业务执业规则（ ...

证券代码：688670 证券简称：金迪克 公告编号：2025-033 江苏金迪克生物技术股份有限公司 关于董事辞职、选举职工代表董事及选举董事会 提名委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏金迪克生物技术股份有限公司（以下简称"公司"）董事会于近日收到 董事夏建国先生提交的辞职报告，夏建国先生因公司治理结构调整原因申请辞 去公司第二届董事会董事、董事会提名委员会委员职务，辞去上述职务后，夏 建国先生将继续在公司担任副总经理职务。根据《中华人民共和国公司法》《上 海证券交易所科创板股票上市规则》及《公司章程》的相关规定，夏建国先生 的辞职报告自送达董事会之日起生效。 2025 年 11 月 11 日，公司召开了第七次职工代表大会，审议通过了《关于 选举公司第二届董事会职工代表董事的议案》，同意选举夏建国先生为公司第二 届董事会职工代表董事，任期自本次职工代表大会审议通过之日起至公司第二 届董事会任期届满之日止。 同日，公司召开了第二届董事会第十五次会议，审议通过了《关于选举董 事会提名委员会委员 ...

南财智讯11月11日电，金迪克公告，公司股票连续2个交易日内（2025年11月10日、2025年11月11日） 收盘价格涨幅偏离值累计达到30%，根据相关规定，属于股票交易异常波动。经公司自查并询证控股股 东及实际控制人，截至公告披露日，公司不存在应披露而未披露的重大信息。公司目前生产经营正常， 未发生重大变化。2025年前三季度，公司营业收入7,465.76万元，同比增长91.93%，归属于上市公司股 东的净利润为-8,647.06万元，扣除非经常性损益后的净利润为-9,111.37万元，仍处于亏损状态，预计 2025年全年存在无法盈利的风险。公司股价近期波动幅度较大，提醒投资者注意投资风险，理性决策。 ...

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.08% on November 11, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 4002.76, down 0.39%, while the Shenzhen Component Index closed at 13289.0, down 1.03% [1] Stock Performance - Notable gainers included: - Jin Ke (688670) with a closing price of 24.97, up 19.99% on a trading volume of 134,300 shares and a transaction value of 310 million [1] - Kanghua Bio (300841) closed at 83.21, up 6.04% with a trading volume of 57,100 shares [1] - Watson Bio (300142) closed at 12.82, up 2.64% with a trading volume of 942,000 shares [1] - Significant losers included: - Bu Yuan Bio (688765) closed at 86.00, down 8.02% with a trading volume of 107,600 shares [2] - Ao Pu Mai (688293) closed at 59.18, down 3.65% with a trading volume of 17,900 shares [2] - Rongchang Bio (688331) closed at 86.00, down 2.55% with a trading volume of 45,900 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 671 million from institutional investors, while retail investors contributed a net inflow of 335 million [2] - The capital flow for key stocks showed: - Jin Ke had a net inflow of 48.11 million from institutional investors, but a net outflow of 24.49 million from speculative funds [3] - Zhifei Bio (300122) experienced a net inflow of 15.25 million from institutional investors, with a net outflow of 23.20 million from retail investors [3] - Kanghua Bio had a net inflow of 14.35 million from institutional investors, but a net outflow of 23.26 million from speculative funds [3]

Group 1 - The vaccine sector experienced a significant rise, with Gendik hitting the daily limit increase [1] - Other companies such as Watson Bio, Zhifei Bio, Kangtai Bio, Baike Bio, and Kangle Weishi also saw gains [1]

Core Viewpoint - The pharmaceutical sector experienced a rebound on November 11, with significant gains in various sub-sectors including chemical pharmaceuticals, innovative drugs, weight loss drugs, and recombinant proteins [2] Group 1: Sector Performance - The chemical pharmaceutical sector showed strong performance, contributing to the overall recovery of the pharmaceutical industry [2] - Innovative drugs also saw notable increases, indicating a positive market sentiment towards new drug developments [2] - Weight loss drugs and recombinant proteins were among the top gainers, reflecting growing consumer interest and demand in these areas [2] Group 2: Individual Stock Movements - Gendik rose over 15%, highlighting its strong market performance within the sector [2] - Hongyuan Pharmaceutical increased by more than 7%, indicating investor confidence in its growth prospects [2] - Other companies such as Nanjing New Pharmaceutical, Hendi Pharmaceutical, Haichen Pharmaceutical, and Tailong Pharmaceutical also experienced upward movements, suggesting a broader trend of recovery among pharmaceutical stocks [2]

Group 1 - The stock price of Gendik (688670.SH), a company in the flu vaccine sector, has seen a significant increase, with a rise of over 10% on November 11 [1] - The latest flu monitoring report from the National Disease Control indicates an increase in flu activity in southern provinces and most northern provinces during the 44th week of 2025 [1] Group 2 - In addition to influenza, there is a need to be vigilant about Respiratory Syncytial Virus (RSV), which has a positive detection rate of 8.5% among severe acute respiratory infection cases in the 44th week of 2025 [2] - RSV is highly contagious and can lead to severe respiratory infections, particularly in infants, with the potential for long-term lung function impairment [2][3] - The peak of RSV infections in China typically occurs in winter and spring, with significant regional differences; northern regions show a clear seasonal pattern, while southern regions experience year-round circulation [3] Group 3 - The current RSV infection peak in Tianjin has arrived 2 to 3 weeks earlier than last year, with RSV positivity rates ranking second, following influenza [3] - Children under 5 years old, especially those under 1 year, are at the highest risk for RSV infections, necessitating preventive measures to avoid severe cases and fatalities [3][4] - The combination of RSV and influenza infections poses a greater disease burden and may strain medical resources, complicating prevention efforts [3][4] Group 4 - Recommendations for prevention include vaccination for children over 6 months against influenza and the use of RSV monoclonal antibodies for infants under 1 year, as there is currently no vaccine for RSV [4] - Non-pharmaceutical interventions such as maintaining social distance, hand hygiene, wearing masks, and improving immunity are also advised, particularly for households with young children [4][5] - The emphasis is on proactive prevention to mitigate the impact on individuals, society, and healthcare resources during the flu season [5]

Group 1 - The closing price of Jindike (688670) on November 10 was 20.81 yuan, reaching the daily limit with a trading volume of 1.35 billion yuan and a turnover rate of 5.59% [1][2] - The stock was listed on the daily trading list due to a price increase of 15% at the close [1] - The top five trading departments accounted for a total transaction amount of 69.02 million yuan, with a net buying amount of 27.68 million yuan [1][2] Group 2 - The main capital inflow for the stock was 18.52 million yuan throughout the day [2] - The largest buying department was Kaiyuan Securities Co., Ltd. with a purchase amount of 18.48 million yuan [2] - The largest selling department was Huatai Securities Co., Ltd. with a selling amount of 5.85 million yuan [2]

Strong Individual Stocks - As of November 10, the Shanghai Composite Index rose by 0.53% to 4018.6 points, while the Shenzhen Component Index increased by 0.18% to 13427.61 points. The ChiNext Index, however, fell by 0.92% to 3178.83 points. A total of 92 stocks in the A-share market hit the daily limit up [1] - The top three strong stocks based on current consecutive limit-up counts and daily trading data are Yingxin Development (000620), Chongqing Construction (600939), and Qingshuiyuan (300437) [1] - Detailed data for the top 10 strong stocks includes consecutive limit-up days and turnover rates, with Yingxin Development showing 6 days and 4 limit-ups at a turnover rate of 13.75% [1] Strong Concept Sectors - The top three concept sectors with the highest gains in the A-share market are Dairy, Cultivated Diamonds, and Baijiu concepts [2] - The Dairy sector increased by 4.36%, Cultivated Diamonds by 3.46%, and Baijiu concepts by 3.01% [3] - Other notable sectors include Tianjin Free Trade Zone (2.97%), Duty-Free Shops (2.76%), and Pre-made Dishes (2.65%) [3]